Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo Biotoscana
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Biotoscana Farma S.A.
- Biotoscana Investments SA
- Biotoscana International